Germline genetic associations for hepatobiliary cancers
P Chotiprasidhi, AK Sato-Espinoza… - Cellular and molecular …, 2023 - Elsevier
Hepatobiliary cancers (HBC) include hepatocellular carcinoma, cholangiocarcinoma, and
gallbladder carcinoma, which originate from the liver, bile ducts, and gallbladder. They are …
gallbladder carcinoma, which originate from the liver, bile ducts, and gallbladder. They are …
Exceptional Response to Olaparib: A Case Report of Metastatic Esophageal Squamous Cell Carcinoma in a Patient With Fanconi Anemia, Germline FANCA Mutation, and …
LR Haggstrom, K Tucker, R Williams, A Nelson… - JCO Precision …, 2023 - ascopubs.org
Exceptional Response to Olaparib: A Case Report of Metastatic Esophageal Squamous Cell
Carcinoma in a Patient With Fanconi Anemia, Germline FANCA Mutation, and Somatic BRCA2 …
Carcinoma in a Patient With Fanconi Anemia, Germline FANCA Mutation, and Somatic BRCA2 …
[HTML][HTML] Genomic landscape of Chinese patients with hepatocellular carcinoma using next-generation sequencing and its association with the prognosis
Z Yang, J Liu, F Xue, L Zhang, H Xue, Y Wu, S Bai… - Annals of …, 2023 - Elsevier
Abstract Introduction and Objectives The occurrence of hepatocellular carcinoma (HCC) is
not entirely clear at present. This study comprehensively described the landscape of genetic …
not entirely clear at present. This study comprehensively described the landscape of genetic …
Genomic profile of Pancoast syndrome due to hepatocellular carcinoma: A case report
DT Bergman, L Zaki, JR Pettus, BI Zaki… - Thoracic Cancer, 2023 - Wiley Online Library
Hepatocellular carcinoma (HCC) is a common cancer and is frequently diagnosed at a late
and unresectable stage with limited effective treatment options. Here, we present the fifth …
and unresectable stage with limited effective treatment options. Here, we present the fifth …
Pharmacokinetic Interaction Between Olaparib and Regorafenib in an Animal Model
D Szkutnik-Fiedler, A Karbownik, F Otto, J Maciejewska… - Pharmaceutics, 2024 - mdpi.com
Background: Olaparib (OLA) and regorafenib (REG) are metabolized by the CYP3A4
isoenzyme of cytochrome P450. Both drugs are also substrates and inhibitors of the …
isoenzyme of cytochrome P450. Both drugs are also substrates and inhibitors of the …
FANCA-deficient cancer cells are sensitized to PARPi and ATRi by homologous recombination-independent mechanisms
S Ellington - 2024 - cdr.lib.unc.edu
PARP inhibitors (PARPi) are a class of DNA damage-inducing drugs currently used in the
clinic to treat cancers with mutations in BRCA1/2, which show elevated sensitivity to PARPi …
clinic to treat cancers with mutations in BRCA1/2, which show elevated sensitivity to PARPi …